ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
https://launchlinks.com/jacemembers
.png)
7200 Powers Ave. #151 Jacksonville, Florida 32217
19047291091
jtparish02@outlook.com
Copyright © 2023 jacenews24. All Rights Reserved
